Steven Valiquette
Stock Analyst at Mizuho
(3.56)
# 838
Out of 5,147 analysts
125
Total ratings
55.38%
Success rate
5.12%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GDRX GoodRx Holdings | Maintains: Neutral | $4 → $3 | $1.87 | +60.43% | 2 | Feb 27, 2026 | |
| HSIC Henry Schein | Maintains: Neutral | $81 → $88 | $82.39 | +6.81% | 7 | Feb 25, 2026 | |
| DOCS Doximity | Maintains: Neutral | $45 → $34 | $24.53 | +38.61% | 4 | Feb 10, 2026 | |
| NVST Envista Holdings | Maintains: Neutral | $24 → $27 | $29.21 | -7.57% | 4 | Feb 10, 2026 | |
| CAH Cardinal Health | Maintains: Outperform | $222 → $235 | $229.23 | +2.52% | 8 | Feb 6, 2026 | |
| MCK McKesson | Maintains: Neutral | $880 → $885 | $987.37 | -10.37% | 5 | Feb 5, 2026 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $13 → $14 | $14.68 | -4.63% | 8 | Jan 20, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $170 → $200 | $190.10 | +5.21% | 13 | Jan 20, 2026 | |
| SOLV Solventum | Upgrades: Outperform | $85 → $100 | $74.20 | +34.77% | 3 | Jan 20, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $47.51 | +1.03% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $28 | $12.33 | +127.09% | 2 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $6 | $2.67 | +124.72% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $340 → $380 | $372.14 | +2.11% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $25.65 | +94.93% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $295 → $325 | $182.01 | +78.56% | 4 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $5.26 | +90.11% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $76.49 | +64.73% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $4.82 | +3.73% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $206.10 | -31.10% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $86.16 | -36.17% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $207.12 | -55.58% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $293.27 | +92.66% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $79.90 | +25.16% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $154.05 | +159.66% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $44.88 | +138.41% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $40.62 | -58.15% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $15.30 | -21.57% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $107.88 | -11.01% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $211.91 | -43.37% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $529.70 | -76.02% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $190.54 | +87.89% | 3 | Dec 6, 2019 |
GoodRx Holdings
Feb 27, 2026
Maintains: Neutral
Price Target: $4 → $3
Current: $1.87
Upside: +60.43%
Henry Schein
Feb 25, 2026
Maintains: Neutral
Price Target: $81 → $88
Current: $82.39
Upside: +6.81%
Doximity
Feb 10, 2026
Maintains: Neutral
Price Target: $45 → $34
Current: $24.53
Upside: +38.61%
Envista Holdings
Feb 10, 2026
Maintains: Neutral
Price Target: $24 → $27
Current: $29.21
Upside: -7.57%
Cardinal Health
Feb 6, 2026
Maintains: Outperform
Price Target: $222 → $235
Current: $229.23
Upside: +2.52%
McKesson
Feb 5, 2026
Maintains: Neutral
Price Target: $880 → $885
Current: $987.37
Upside: -10.37%
DENTSPLY SIRONA
Jan 20, 2026
Maintains: Neutral
Price Target: $13 → $14
Current: $14.68
Upside: -4.63%
Align Technology
Jan 20, 2026
Maintains: Outperform
Price Target: $170 → $200
Current: $190.10
Upside: +5.21%
Solventum
Jan 20, 2026
Upgrades: Outperform
Price Target: $85 → $100
Current: $74.20
Upside: +34.77%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $47.51
Upside: +1.03%
Dec 10, 2025
Maintains: Outperform
Price Target: $36 → $28
Current: $12.33
Upside: +127.09%
Nov 19, 2025
Maintains: Neutral
Price Target: $8 → $6
Current: $2.67
Upside: +124.72%
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $372.14
Upside: +2.11%
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $25.65
Upside: +94.93%
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $182.01
Upside: +78.56%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $5.26
Upside: +90.11%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $76.49
Upside: +64.73%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $4.82
Upside: +3.73%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $206.10
Upside: -31.10%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $86.16
Upside: -36.17%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $207.12
Upside: -55.58%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $293.27
Upside: +92.66%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $79.90
Upside: +25.16%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $154.05
Upside: +159.66%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $44.88
Upside: +138.41%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $40.62
Upside: -58.15%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $15.30
Upside: -21.57%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $107.88
Upside: -11.01%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $211.91
Upside: -43.37%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $529.70
Upside: -76.02%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $190.54
Upside: +87.89%